Loading stock data…
AURA
$7.01-0.04 (-0.57%)
Market ClosedLast close May 1
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aura Biosciences, Inc. in the Healthcare sector is trading at $7.01. The stock is currently 9% below its 52-week high of $7.68, remaining 14.0% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why AURA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.01
Potential Upside
5%
Whystock Fair Value$7.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$20.40+191.0%
Range$15.00 – $26.00
Fundamentals
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$480.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.32%
Volume
Today's trading volume
197,067
Recent News
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 201.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.